Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.
GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.
NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.
Comgy GmbH, founded in 2017 and based in Berlin, Germany, specializes in digital metering solutions for the housing and energy sectors. The company offers a range of products, including a sub-metering solution that allows users to read meters, and applications for meter gateway management and installation management. These tools facilitate remote device configuration, data processing, and digital registration of measurements, supported by photographic documentation. Additionally, Comgy provides a gateway that enables secure communication between meters, sensors, and its customer platform. By digitizing the measurement, visualization, and billing of heat, water, and electricity consumption in real estate, Comgy helps businesses compile transparent statements of accounts, ultimately promoting energy savings and reducing unnecessary costs.
Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.
Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.
Kodiak Sciences is designing and developing novel therapies for the treatment of retinal disease. As a rapidly growing biopharmaceutical company, we are working every day to build value for the benefit of our community of patients, physicians, employees, families, and vendors. We want to have real impact, and we take a long term view. We are committed to ethics and excellence in everything we do. We are looking to hire top talent comfortable with ownership and accountability of exciting programs while collaborating effectively with colleagues inside and outside the company.
ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. It specializes in a platform that utilizes data from small molecules or metabolites to derive actionable insights. The company's technology employs a network-based machine learning algorithm for the integrative analysis of untargeted metabolomic data alongside large-scale molecular information, which includes data from genes, proteins, drugs, and diseases. This innovative approach enables researchers to develop in-house therapeutics specifically targeting patients with liver diseases and related conditions, thereby aiming to improve health outcomes through the unlocking of metabolomic data's potential.
GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.
Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.
Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.
Force of Nature manufactures electronic appliances designed to create a cleaning solution using basic ingredients found at home.
N12 Technologies, Inc. specializes in the manufacturing and supply of advanced nano-composite materials aimed at enhancing the performance of composite products in various industries, including aerospace, automotive, and consumer goods. The company offers innovative solutions such as NanoStitch, which reinforces the interlaminar region during composite lay-up, and the Surface Layer System, which improves thermal and electrical conductivity for applications like surface curing and deicing. Utilizing technology licensed from MIT, N12 produces vertically-aligned carbon nanotube forests that enhance shear strength, fatigue life, and impact resistance while preventing crack growth and delamination. Founded in 2012 and headquartered in Somerville, Massachusetts, N12 Technologies aims to provide cost-effective, high-performance materials that seamlessly integrate into existing fabrication processes without requiring modifications.
Zipline Inc. is a California-based company that specializes in designing, manufacturing, and operating drones for the delivery of essential medical supplies, including vaccines, medicines, and blood. Founded in 2011 and headquartered in Half Moon Bay, the company aims to provide instant access to vital medical products for every individual globally. Since its inception, Zipline has developed a rapid delivery drone and an autonomous logistics network, allowing for efficient distribution to hospitals and health centers, particularly in remote areas. By leveraging its proprietary fixed-wing drone technology, Zipline facilitates timely deliveries that support the medical community and enhance patient care.
Aircuity manufactures integrated sensing and control solutions that cost-effectively reduce building energy and operating expenses while simultaneously improving its indoor environmental quality. Aircuity's first product, a portable air monitoring system known as OptimaTM, it was developed in collaboration with Environmental Health & Engineering, the primary research contractor for the EPA's Indoor Environments Division. It was incorporated in 2000 and is headquartered in Newton, Massachusetts.
N12 Technologies, Inc. specializes in the manufacturing and supply of advanced nano-composite materials aimed at enhancing the performance of composite products in various industries, including aerospace, automotive, and consumer goods. The company offers innovative solutions such as NanoStitch, which reinforces the interlaminar region during composite lay-up, and the Surface Layer System, which improves thermal and electrical conductivity for applications like surface curing and deicing. Utilizing technology licensed from MIT, N12 produces vertically-aligned carbon nanotube forests that enhance shear strength, fatigue life, and impact resistance while preventing crack growth and delamination. Founded in 2012 and headquartered in Somerville, Massachusetts, N12 Technologies aims to provide cost-effective, high-performance materials that seamlessly integrate into existing fabrication processes without requiring modifications.
Lumicell, Inc. specializes in developing image-guided cancer surgery solutions aimed at enhancing surgical outcomes for patients with various types of cancer, including breast cancer and sarcoma. The company has created an intraoperative imaging system that utilizes a handheld device in conjunction with a cancer-specific optical contrast agent. This system provides real-time visual feedback on the presence of residual cancer cells within the tumor bed, allowing surgeons to effectively remove any remaining cancerous tissue during the procedure. By illuminating cancer cells, Lumicell's technology aims to minimize the need for repeat surgeries due to positive margins and local recurrence, thereby improving patient outcomes. The company is also exploring applications of its technology in other cancers, such as colorectal cancer and pancreatic cancer. Founded in 2008 and based in Wellesley, Massachusetts, Lumicell continues to advance its clinical investigations to validate the effectiveness and safety of its innovative surgical solutions.